The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Open accessAbstract
Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 +/- 3 years, fasting plasma glucose 152 +/- 9 mg/dl, BMI 30.6 +/- 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 +/- 4 vs. 82 +/- 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 +/- 3 vs. 7 +/- 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 +/- 3 to 14 +/- 3%, NS). Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = -0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator-activated receptor-gamma, adiponectin, and lipoprotein lipase in adipose tissue. In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. The decrease in liver fat by rosiglitazone is associated with an increase in serum adiponectin concentrations. Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reductions in hepatic steatosis with both pioglitazone and rosig litazone ameliorate hepatic insulin resistance.134,135”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [135]
In the citing paper
“We have previously shown that metformin does not change liver fat content.35”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,673
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
Combs, T. P., Berg, A. H., Obici, S., Scherer, P. E., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14120 · Cited by 955
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Cited by
Sorted by citations
Items 101–200 of 524
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Lu, W., Li, S., Li, J., Wang, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., et al. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/1459790 · Cited by 130
Nobili, V., Manco, M., Ciampalini, P., Alisi, A., Vito, R. D., Bugianesi, E., MARCELLINI, M., & Marchesini, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.06.012 · Cited by 125
Treatment of non-alcoholic fatty liver disease.
(2007) · PubMed Central · Cited by 118
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
Omer, Z., Çetinkalp, Ş., Akyıldız, M., Yılmaz, F., Batur, Y., Yılmaz, C., & Akarca, U. S. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832e2baf · Cited by 117
Rasouli, N., Yao‐Borengasser, A., Miles, L. M., Elbein, S. C., & Kern, P. A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00240.2005 · Cited by 116
Human genetics of adiponectin in the metabolic syndrome
Yang, W., & Chuang, L. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0011-7 · Cited by 115
Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside
Gariani, K., Philippé, J., & Jornayvaz, F. R. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.11.002 · Cited by 113
Pioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S. A., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 115
Liver disease and diabetes: Association, pathophysiology, and management
Ahmadieh, H., & Azar, S. T. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.003 · Cited by 112
Rosiglitazone decreases albuminuria in type 2 diabetic patients
Miyazaki, Y., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2007) · Kidney International · doi:10.1038/sj.ki.5002516 · Cited by 112
Yan, J., Feng, Z., Liu, J., Shen, W., Wang, Y., Wertz, K., Weber, P., Long, J., & Liu, J. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.014 · Cited by 114
Baranova, A. V., Gowder, S., Schlauch, K. A., Elariny, H. A., Collantes, R. S., Afendy, A., Ong, J. P., Goodman, Z. D., Chandhoke, V., & Younossi, Z. M. (2006) · Obesity Surgery · doi:10.1381/096089206778392149 · Cited by 111
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Ali, R., & Cusi, K. J. (2009) · Annals of Medicine · doi:10.1080/07853890802552437 · Cited by 111
Ectopic fat and insulin resistance
Lettner, A., & Roden, M. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0032-z · Cited by 106
Nadeau, K. J., Ehlers, L. B., Zeitler, P. S., & Love‐Osborne, K. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00450.x · Cited by 106
Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells
Yang, X., Xu, Z., Zhang, C., Cai, Z., & Zhang, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.019 · Cited by 108
Thomas, E. L. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i36.5813 · Cited by 102
Lessard, S. J., Rivas, D. A., Chen, Z.-P., Bonen, A., Febbraio, M. A., Reeder, D. W., Kemp, B. E., Yaspelkis, B. B., & Hawley, J. A. (2007) · Diabetes · doi:10.2337/db06-1065 · Cited by 103
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W. J. C., Garcia-Garcia, H., van Es, G., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 102
Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Blanco-Rojo, R., Alcala-Diaz, J. F., Wopereis, S., Pérez‐Martínez, P., Quintana‐Navarro, G. M., Marı́n, C., Ordovás, J. M., van Ommen, B., Pérez‐Jiménez, F., Delgado‐Lista, J., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3776-4 · Cited by 104
Obesity, Inflammation, and Vascular Disease
Calabrò, P., & Yeh, E. T. H. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_3 · Cited by 101
Mulligan, K. M., Yang, Y., Wininger, D. A., Koletar, S. L., Parker, R. A., Alston‐Smith, B., Schouten, J. T., Fielding, R. A., Basar, M. T., & Grinspoon, S. K. (2006) · AIDS · doi:10.1097/qad.0b013e328011220e · Cited by 97
Bojsen-Møller, K. N., Lundsgaard, A., Madsbad, S., Kiens, B., & Holst, J. J. (2018) · Diabetes · doi:10.2337/db18-0539 · Cited by 97
Läutamaki, R., Airaksinen, J. K. E., Seppänen, M., Toikka, J., Luotolahti, M., Ball, E., Borra, R., Härkönen, R., Iozzo, P., Stewart, M. W., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2787 · Cited by 98
The effect of thiazolidinediones on adiponectin serum level: a meta‐analysis
Riera‐Guàrdia, N., & Rothenbacher, D. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00755.x · Cited by 91
Recent findings concerning thiazolidinediones in the treatment of diabetes
Boden, G. H., & Zhang, M. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.243 · Cited by 93
Teranishi, T., Ohara, T., Maeda, K., Zenibayashi, M., Kouyama, K., Hirota, Y., Kawamitsu, H., Fujii, M., Sugimura, K., & Kasuga, M. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.005 · Cited by 93
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 92
Pharmacotherapy of Childhood Obesity
Freemark, M. (2007) · Diabetes Care · doi:10.2337/dc06-1569 · Cited by 90
Ni, X., & Wang, H. (2016) · PubMed Central · Cited by 89
Non-alcoholic Fatty Liver Disease in Children
Manco, M., Bottazzo, G. F., Vito, R. D., Marcellini, M., Mingrone, G., & Nobili, V. (2008) · touchREVIEWS in Endocrinology · doi:10.1080/07315724.2008.10719744 · Cited by 85
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Huypens, P., Quartier, E., PIPELEERS, D. G., & de Casteele, M. V. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.06.016 · Cited by 86
Kolak, M., Yki‐Järvinen, H., Kannisto, K., Tiikkainen, M., Hamsten, A., Eriksson, P. O., & Fisher, R. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1465 · Cited by 86
The Effect of Pioglitazone on the Liver
Gastaldelli, A., Miyazaki, Y., Mahankali, A., Berria, R., Pettiti, M., Buzzigoli, E., Ferrannini, E., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2445 · Cited by 86
The metabolic syndrome and nonalcoholic fatty liver disease in children
Sundaram, S. S., Zeitler, P. S., & Nadeau, K. J. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32832cb16f · Cited by 85
Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Bajaj, M. S., Baig, R., Suraamornkul, S., Hardies, L. J., Coletta, D. K., Cline, G. W., Monroy, A., Koul, S., Sriwijitkamol, A., Musi, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0911 · Cited by 86
Thiazolidinediones, insulin resistance and obesity: finding a balance
Wilding, J. P. H. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01128.x · Cited by 84
Calabrò, P., & Yeh, E. T. H. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0008-z · Cited by 84
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Vella, V., Nicolosi, M. L., Giuliano, S., Bellomo, M., Belfiore, A., & Malaguarnera, R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00031 · Cited by 82
van Poelje, P. D., Potter, S. C., Chandramouli, V. C., Landau, B. R., Dang, Q., & Erion, M. D. (2006) · Diabetes · doi:10.2337/db05-1443 · Cited by 87
Liu, G., Ding, M., Chiuve, S. E., Rimm, E. B., Franks, P. W., Meigs, J. B., Hu, F. B., & Sun, Q. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308320 · Cited by 80
Anti-diabetic effects of Sutherlandia frutescens in Wistar rats fed a diabetogenic diet
Chadwick, W., Roux, S., van de Venter, M., Louw, J., & Oelofsen, W. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.07.012 · Cited by 83
Zib, I., Jacob, A. N., Lingvay, I., Salinas, K., McGavock, J., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00003 · Cited by 79
Liu, L.-F., Purushotham, A., Wendel, A. A., & Belury, M. A. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00523.2006 · Cited by 77
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
VanWagner, L. B., & Rinella, M. E. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11403809 · Cited by 77
Therapeutic Trials in Nonalcoholic Steatohepatitis
Ratziu, V., Caldwell, S. H., & Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.24042 · Cited by 76
Non‐alcoholic fatty liver disease is associated with cardiovascular disease risk markers
Edens, M. A., Kuipers, F., & Stolk, R. P. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00594.x · Cited by 77
Wu, H., Jia, W., Bao, Y., Lu, J., Zhu, J., Wang, R., Chen, Y., & Xiang, K. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.016 · Cited by 75
Insulin resistance and hepatitis C: an evolving story
Eslam, M., Khattab, M. A., & Harrison, S. A. (2011) · Gut · doi:10.1136/gut.2010.228262 · Cited by 74
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., DeFronzo, R. A., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1159 · Cited by 75
Ahmed, M., Neville, M. J., Edelmann, M. J., Kessler, B. M., & Karpe, F. (2009) · Obesity · doi:10.1038/oby.2009.208 · Cited by 73
Pfützner, A., Schöndorf, T., Seidel, D., Winkler, K., Matthaei, S., Hamann, A., & Forst, T. M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.06.021 · Cited by 70
The Influence of Maca (Lepidium meyenii) on Antioxidant Status, Lipid and Glucose Metabolism in Rat
Večeřa, R., Orolin, J., Škottová, N., Kazdová, L., Oliyarnyk, O., Jitka Ulrichová, A., & Šimánek, V. (2007) · Plant Foods for Human Nutrition · doi:10.1007/s11130-007-0042-z · Cited by 71
Kim, H. J., Kang, E. S., Kim, D. J., Kim, S. H., Ahn, C. W., Soo, B., Nam, M., Chung, C. H., Lee, K. W., Nam, C. M., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02723.x · Cited by 71
Oberbach, A., Lehmann, S., Kirsch, K., Krist, J., Sonnabend, M., Linke, A., Tönjes, A., Stümvoll, M., Blüher, M., & Kovacs, P. L. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0220 · Cited by 69
The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer
Ferguson, R. D., Gallagher, E. J., Scheinman, E. J., Damouni, R., & LeRoith, D. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00010-1 · Cited by 72
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 72
Montecucco, F., Steffens, S., & Mach, F. (2008) · Mediators of Inflammation · doi:10.1155/2008/767623 · Cited by 62
Wargent, E. T., Sennitt, M. V., Stocker, C. J., Mayes, A. E., Brown, L., O’Dowd, J. F., Wang, S., Einerhand, A. W. C., Mohede, I., Arch, J. R. S., et al. (2005) · Lipids in Health and Disease · doi:10.1186/1476-511x-4-3 · Cited by 66
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?
Malaguarnera, R., Vella, V., Nicolosi, M. L., & Belfiore, A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00314 · Cited by 68
Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetes · doi:10.2337/db07-0827 · Cited by 63
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63
Liu, M., & Liu, F. (2012) · Biochimie · doi:10.1016/j.biochi.2012.01.008 · Cited by 64
Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection
Buckingham, R. E. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.09.027 · Cited by 62
Scheen, A. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.902444 · Cited by 61
Insulin Production and Resistance in Different Models of Diet-Induced Obesity and Metabolic Syndrome
Alwahsh, S. M., Dwyer, B. J., Forbes, S., Thiel, D. H. V., Lewis, P. J. S., & Ramadori, G. P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020285 · Cited by 63
Borra, R., Läutamaki, R., Parkkola, R. K., Komu, M. E. S., Sijens, P. E., Hällsten, K., Bergman, J. R., Iozzo, P., & Nuutila, P. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.015 · Cited by 60
Pharmacological agents for NASH
Ratziu, V. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.193 · Cited by 59
Razavizade, M., Jamali, R., Arj, A., Matini, S. M., Moraveji, A., & Taherkhani, E. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9270 · Cited by 59
Thiazolidinediones and the liver in humans
Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 60
Brooks, N. L., Moore, K. S., Clark, R. D., Perfetti, M. T., Trent, C. M., & Combs, T. P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00596.x · Cited by 59
Bobulescu, I. A., Dubree, M., Zhang, J., McLeroy, P., & Moe, O. W. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00177.2009 · Cited by 57
DiNicolantonio, J. J., McCarty, M. F., & O’Keefe, J. H. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 59
Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans
Vega, G. L., Chandalia, M., Szczepaniak, L. S., & Grundy, S. M. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318177024d · Cited by 56
Shah, P., Mudaliar, S. R. D., Chang, A. R., Aroda, V. R., André, M., Burke, P., & Henry, R. R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01370.x · Cited by 55
In vitro and in vivo Effects of Metformin on Human Adipose Tissue Adiponectin
Zulian, A., Cancello, R., Girola, A., Gilardini, L., Alberti, L., Croci, M., Micheletto, G., Danelli, P., & Invitti, C. (2011) · Obesity Facts · doi:10.1159/000324582 · Cited by 56
Kato, M., Shibata, R., Obata, K., Miyachi, M., Yazawa, H., Tsuboi, K., Yamada, T., Nishizawa, T., Noda, A., Cheng, X. W., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328302f0f7 · Cited by 56
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 57
Sharma, P. K., Bhansali, A. K., Sialy, R., Malhotra, S., & Pandhi, P. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02658.x · Cited by 54
Beddhu, S., Filipowicz, R., Wang, B., Wei, G., Chen, X., Roy, A. C., DuVall, S. L., Farrukh, H. M., Habib, A. N., Bjordahl, T. S., et al. (2016) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358116675343 · Cited by 53
Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes
Lingvay, I., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.02.005 · Cited by 55
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale, S. E. (2009) · Frontiers in bioscience · doi:10.2741/3301 · Cited by 55
Bak, E. J., Park, H. G., Kim, J. M., Kim, J. M., Yoo, Y.-J., & Cha, J.-H. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.223 · Cited by 54
Krššák, M., Hofer, H., Wrba, F., Meyerspeer, M., Brehm, A., Lohninger, A., Steindl‐Munda, P., Moser, E., Ferenci, P., & Roden, M. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.03.062 · Cited by 54
Home, P. D., & Pacini, G. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00761.x · Cited by 55
Nocapyrones: α- and γ-Pyrones from a Marine-Derived Nocardiopsis sp.
Kim, Y., Ogura, H., Akasaka, K., Oikawa, T., Matsuura, N., Imada, C., Yasuda, H., & Igarashi, Y. (2014) · Marine Drugs · doi:10.3390/md12074110 · Cited by 53
Phillips, S. A., Kung, J., Ciaraldi, T. P., Choe, C. H., Christiansen, L., Mudaliar, S. R. D., & Henry, R. R. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00378.2009 · Cited by 53
Lee (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000412 · Cited by 52
Adipose tissue fatty acid metabolism and cardiovascular disease
Frayn, K. N., Fielding, B. A., & Karpe, F. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000171919.62129.6b · Cited by 52
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 57
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 52
Choi, D., Jung, C., Mok, J., Kim, C., Kang, S.-K., & Kim, B. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.3.387 · Cited by 50
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., & Petta, S. (2018) · Pharmaceuticals · doi:10.3390/ph11040121 · Cited by 53
The Multifaceted Associations of Hepatobiliary Disease and Diabetes
Bell, D. S. H., & Allbright, E. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.300 · Cited by 51
Metformin and pioglitazone: effectively treating insulin resistance
Staels, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112732 · Cited by 51
Hollingsworth, K. G., Abubacker, M., Joubert, I., Allison, M., & Lomas, D. J. (2006) · British Journal of Radiology · doi:10.1259/bjr/23166141 · Cited by 51
Catalano, D., Trovato, G. M., Martines, G. F., Randazzo, M., & Tonzuso, A. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01742.x · Cited by 50
Metadata
- Authors
- Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H.
- Affiliations
- University of Helsinki (FI)
- Department of Medicine, Division of Oncology, University of Helsinki, Helsinki, Finland
- Minerva Foundation (FI)
- Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2004-08-01
- Volume
- 53
- Issue
- 8
- Pages
- 2169-2176
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2107068945
- Cited by
- 524
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 15 · 2017: 12 · 2016: 18 · 2015: 19 · 2014: 24 · 2013: 26 · 2012: 15
- FWCI
- 34.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Suomen Lääketieteen Säätiö
- Biomedicum Helsinki-säätiö
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, metformin, type 2 diabetes, hepatic insulin resistance, hepatic insulin sensitivity, liver fat, insulin clearance, adiponectin, adipose tissue gene expression, PPARγ, lipoprotein lipase, insulin-stimulated glucose uptake, 1H NMR, drug comparison, weight loss, HbA1c
- MeSH terms
- Rosiglitazone, Adipose Tissue, Cholesterol, Diabetes Mellitus, Type 2, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Male, Metformin, Middle Aged, Triglycerides, Thiazolidinediones, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
